Business article - February 16, 2021
Medtech – A hotter investment sector than ever, shows new analysis
The communications consultancy company Paues Åberg has analyzed the investment interest of the Swedish life science sector and found that investments in the field of medtech has increased by 235% during the last two years. “A good approach to understand the latest trends within investor relations is to analyze raised capital in different industries and […]
Collaboration - February 10, 2021
NOME secures DKK 13.5 million in funding
The Nordic Mentor Network of Entrepreneurship (NOME), a Mentoring Program for Nordic life science startups, has secured new funding from the Novo Nordisk Foundation for the next three years. The new funding from the Novo Nordisk Foundation will allow NOME to expand its operations by onboarding more companies, new mentors, additional partner organizations, exploring new […]
Financing - February 5, 2021
Devyser completes private placement of SEK 130 million
Devyser Diagnostics has announced the completion of a private placement of 7,465 shares, corresponding to SEK 130 million before issuance costs, to Swedbank Robur and the Fourth Swedish National Pension Fund (AP4). The purpose of the issue is primarily to finance the company’s global marketing and sales expansion. As part of the private placement, Swedbank […]
Financing - January 11, 2021
“Be bold and clear about clinical ambitions”
Nordic Life Science asked Claus Andersson, General Manager at Sunstone Life Science Venture, what Nordic venture capitalists are looking for today within life sciences and what current opportunities and challenges Nordic life science companies facing when it comes to raising capital. Copenhagen-based Sunstone Life Science Venture is an independent European venture capital investment firm. Claus […]
Financing - January 10, 2021
“Build the best possible and truly diverse team”
Nordic Life Science asked Inka Mero, Founder and Managing Partner at Voima Ventures, what Nordic venture capitalists are looking for today within life sciences and what current opportunities and challenges Nordic life science companies facing when it comes to raising capital.
Biotech Business - December 16, 2020
Cantargia has completed a directed share issue of approximately SEK 564 million
Investors in the Directed Share Issue are a wide range of Swedish and international investors, including AFA Försäkring, Swedbank Robur, Invus Public Equities LP, Point72 Asset Management, Handelsbanken Fonder and Granite Point Capital. The net proceeds from the Directed Share Issue are intended to be used to advance the company’s lead drug candidate, CAN04, which […]
